logo
Plus   Neg
Share
Email

Sangamo, Pfizer Report Promising Interim Results With SB-525 Gene Therapy

Sangamo Therapeutics, Inc. (SGMO) and Pfizer, Inc. (PFE) announced interim data from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. The company said the data indicate that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII levels across the four dosage cohorts. Based on the results, the Safety Monitoring Committee recommended cohort expansion at the 3e13 vg/kg dose.

The U.S. FDA has granted Orphan Drug and Fast Track designations to SB-525, which also received Orphan Medicinal Product designation from the European Medicines Agency. SB-525 is being developed as part of a global collaboration between Sangamo and Pfizer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Swiss food giant Nestle SA said it is committed to achieving zero net greenhouse gas emissions by 2050, noting that climate change is one of the biggest threats faced by the world. As part of its efforts to achieve the goal, Nestle said it will launch more plant-based food and beverage options that are more environment friendly. Coffee giant Starbucks Corp. is set to open the world's largest Starbucks Reserve Roastery on November 15 on Chicago's Magnificent Mile. It will open in an interactive four-storey glass-clad building in 43,000 square feet space, employing about 200 people. The site at the corner of North Michigan Avenue and Erie Street was previously occupied by Crate & Barrel. United Parcel Service Inc. agreed to pay $8.4 million to the United States to settle allegations that it overcharged federal agencies for package delivery services, the U.S. Justice Department said. Under a General Services Administration or GSA contract, UPS was required to provide GSA with certain lower prices for its services.
Follow RTT